Cutler Group’s Anavex Life Sciences AVXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-17,400
Closed -$9K 3775
2022
Q4
$9K Buy
17,400
+10,100
+138% +$108K ﹤0.01% 2749
2022
Q3
$6K Sell
7,300
-200
-3% -$2.11K ﹤0.01% 3457
2022
Q2
$5K Sell
7,500
-26,200
-78% -$248K ﹤0.01% 3670
2022
Q1
$15K Buy
+33,700
New +$414K ﹤0.01% 3266
2021
Q3
Sell
-6,600
Closed -$2K 5684
2021
Q2
$2K Buy
6,600
+4,300
+187% +$63.7K ﹤0.01% 4938
2021
Q1
$4K Buy
+2,300
New +$25.1K ﹤0.01% 4469
2017
Q4
Sell
-26,200
Closed -$15K 4873
2017
Q3
$15K Sell
26,200
-10,300
-28% -$45.8K ﹤0.01% 3397
2017
Q2
$30K Sell
36,500
-4,600
-11% -$26.6K ﹤0.01% 2986
2017
Q1
$59K Sell
41,100
-2,900
-7% -$15K ﹤0.01% 2223
2016
Q4
$18K Buy
44,000
+4,000
+10% +$14.3K ﹤0.01% 3550
2016
Q3
$18K Buy
40,000
+18,900
+90% +$79.6K ﹤0.01% 3517
2016
Q2
$22K Buy
21,100
+15,100
+252% +$72.9K ﹤0.01% 3241
2016
Q1
$3K Sell
6,000
-600
-9% -$2.64K ﹤0.01% 5203
2015
Q4
$8K Buy
+6,600
New +$47K ﹤0.01% 4356

Other funds holding AVXL

Cutler Group's AVXL Position: Q1 2023 in Review

Cutler Group sold out of Anavex Life Sciences (AVXL) in Q1 2023, closing a stake of 1,500 shares — an estimated $13K sold.

Cutler Group first reported a position in AVXL in Q4 2015 and held it in 17 quarters. The position peaked at $72K in Q3 2017. 141 funds tracked by Wall St. Rank hold AVXL as of Q1 2023.

  • Cutler Group reported no remaining Anavex Life Sciences position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 1,500 Anavex Life Sciences shares in Q1 2023, an estimated $13K.
  • Cutler Group first reported a position in Anavex Life Sciences in Q4 2015 and held it in 17 quarters.
  • Cutler Group's Anavex Life Sciences position peaked at $72K in Q3 2017.
  • 141 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.